37 results about "Mad Cow Diseases" patented technology

The invention provides cloned transgenic ungulates (e.g., bovines) in which prion protein activity is reduced by one or more genetically engineered mutations. Desirably, these transgenic bovines are also genetically modified to express xenogenous (e.g., human) antibodies. Because of their resistance to prion-related diseases such as bovine spongiform encephalopy (also known as mad cow disease), these bovines are a safer source of human antibodies for pharmaceutical uses and a safer source of agricultural products.

Disclosed herein are compounds and methods for decreasing PrP and preventing, ameliorating, or treating a prion disease or conformational neurodegenerative disorder, in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to PrP include Creutzfeldt-Jakob disease (CJD); variant Creutzfeldt-Jakob Disease (vCJD); Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia; kuru; Bovine Spongiform Encephalopathy (BSE), e.g. “mad cow disease”; Chronic Wasting Disease (CWD); scrapie; transmissible mink encephalopathy; feline spongiform encephalopathy; ungulate spongiform encephalopathy; Alzheimer's disease; Parkinson's disease; Huntington's disease; and Amyotrophic Lateral Sclerosis (ALS).

The invention provides a kind of nicergoline preparation with excellent stability, which is prepared by freeze-drying a nicergoline medicinal solution, and every 1000 g of the nicergoline medicinal solution contains: 2-4 g of nicergoline, 0.5 g of tartaric acid -1g, 0.2-9g of sodium chloride, 20-40g of excipients, and an appropriate amount of water for injection, and the pH of the drug solution is 3.0-5.0. In the formula of the present invention, the lactose in the original preparation is replaced by mannitol as the freeze-drying excipient, which can avoid the risk of allergy, pyrogen, and mad cow disease caused by lactose used as an injection auxiliary material from the source, And it overcomes the instability caused by not using lactose in the prior art. The most notable feature of the present invention is that mannitol, sorbitol, etc. are combined with sodium chloride, so that Nicergoline for injection can still have excellent stability without using lactose. The freeze-dried product of the invention is reconstituted quickly, has a loose appearance, and is convenient for transportation, preservation and clinical use.

Transgenic and cloned ungulates and particularly cloned cattle are disclosed, wherein such cattle contain a deletion or disruption of the prion gene locus and do not express functional prion protein, and are not susceptible to prion-related diseases such as bovine spongiform encephalopy or Mad Cow Disease.

The present invention discloses a preparation method for prion protein gene knockout domestic animals. The process is characterized by: knocking off the prion protein gene of domestic animals on a cellular level; and preparing prion protein gene knockout domestic animals through somatic cell cloning method. The function of the prion protein of domestic animals is inactivated. The functional prion protein is not expressed, thus the domestic animals can resist to relative disease of prion protein, such as scrapie, bovine spongiform encephalopathy (mad cow disease) and the like.

The present invention provides cloned transgenic ungulates (eg, cattle) in which the activity of a prion protein is reduced by one or more genetically engineered mutations. Desirably, these transgenic cattle are also genetically modified to express exogenous (eg, human) antibodies. These cattle are a safer source of human antibodies for medicinal purposes and a safer source of agricultural products due to their protection against prion-related diseases such as bovine spongiform encephalopathy (also known as mad cow disease).

The invention discloses a large-scale preparation method for foot-and-mouth disease totivirus marked vaccine with high yield, high purity and high safety and a product thereof. The method comprises the following steps: a)collecting a virus solution; b)performing deep filtration on a membrane, performing ultrafiltration and performing enzymolysis on nuclease; c)purifying through a strong anion exchange adsorption bed or an adsorption film; d)depositing by PEG, extracting by chloroform-isoamyl aleohl; e)inactivating; F)performing density gradient centrifugation on an inactivation liquid through cane sugar and purifying; g)performing ultrafiltration dialysis and aseptic filtration; and h)reserving a stock solution or emulsifying. The provided foot-and-mouth disease totivirus marked vaccine antigen is uniform and complete foot-and-mouth virus particle, The vaccine is injected into body, so animal infection and immunization can be completely distinguished, does not contain foot-and-mouth disease virus non-structural protein and other virus particle, and does not contain animal-based foreign protein, polypeptide and oligopeptides, animal latent anaphylactic reaction, carcinogenesis and latent risk such as mad cow disease for causing animal infectious diseases due to vaccine injection can be effectively reduced, and the vaccine has no influence on animal food safety and trade.